Research, Development, And Testing Services - Insider Trading Data

Insiders are officers, directors, or significant investors. This page shows insider sentiment and transactions for the Research, industry. Research shows that insider trades are predictive of future stock returns. By examining insider trades for an industry, we can understand what well-informed people think of the overall future industry prospects.

Research, Development, And Testing Services - Insider Buy/Sell Ratio

Insider selling and buying is a useful indicator for analyzing the market because it serves as a proxy for their optimism or pessimism in their own companies. By looking at ratio of total selling and buying across the entire market, we might be able to draw some conclusions about the future market.

We offer two charts here. The first one shows the total dollar volume of buying and selling by insiders. The second chart shows the ratio of the number of insiders selling, vs. the number of insiders buying. In both charts, we filter out trades made by indirect holders (such as trusts), and 10% owners (who, although considered an 'insider' by the SEC, do not actually manage the companies in which they are considered insiders).

Corporate Insider Buy Sell Ratio (Dollar Volume) - Research, Development, And Testing Services
Corporate Insider Buy Sell Ratio (Insider Count) - Research, Development, And Testing Services
Research, Development, And Testing Services - Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Security Form Insider Code 10b5-1 Direct Share
Price
Shares
Changed
2025-06-30 INCY / Incyte Corporation 4 HARRIGAN EDMUND A - Award D 68.10 367
2025-06-30 INCY / Incyte Corporation 4 BAKER BROS. ADVISORS LP See Footnotes A - Award I 492
2025-06-30 INCY / Incyte Corporation 4 Clancy Paul J A - Award D 68.10 361
2025-06-26 INCY / Incyte Corporation 4 Hoppenot Herve A - Award D 6,016
2025-06-25 MXCT / MaxCyte, Inc. 4 Hemrajani Rekha S - Sale D 2.0945 -10,684
2025-06-18 MXCT / MaxCyte, Inc. 4 BALTHROP PATRICK J A - Award D 29,210
2025-06-18 MXCT / MaxCyte, Inc. 4 Hemrajani Rekha A - Award D 29,210
2025-06-18 MXCT / MaxCyte, Inc. 4 Al-Wakeel Yasir B. A - Award D 29,210
2025-06-18 MXCT / MaxCyte, Inc. 4 DOUGLAS RICHARD A - Award D 29,210
2025-06-18 MXCT / MaxCyte, Inc. 4 Collins Cynthia A - Award D 29,210
2025-06-18 MXCT / MaxCyte, Inc. 4 Brooke William W A - Award D 29,210
2025-06-18 MXCT / MaxCyte, Inc. 4 Johnston John Joseph A - Award D 29,210
2025-06-18 MXCT / MaxCyte, Inc. 4 Erck Stanley C A - Award D 29,210
2025-06-17 OABI / OmniAb, Inc. 4 Bertozzi Carolyn R M - Exercise D 20,000
2025-06-17 OABI / OmniAb, Inc. 4 Love Steven M - Exercise D 20,000
2025-06-17 OABI / OmniAb, Inc. 4 HIGGINS JOHN L M - Exercise D 20,000
2025-06-17 OABI / OmniAb, Inc. 4 Cochran Jennifer R. M - Exercise D 20,000
2025-06-11 ABSI / Absci Corporation 4 Pangalos Menelas N A - Award D 14,500
2025-06-11 ABSI / Absci Corporation 4 MCGINNIS KAREN K A - Award D 14,500
2025-06-11 ABSI / Absci Corporation 4 Rabinovitsj Daniel A A - Award D 14,500
2025-06-11 ABSI / Absci Corporation 4 Houten Frans Van A - Award D 14,500
2025-06-11 ABSI / Absci Corporation 4 Sirosh Joseph A - Award D 14,500
2025-06-10 INCY / Incyte Corporation 4 Schaffert Susanne F - Taxes D 70.07 -849
2025-06-10 INCY / Incyte Corporation 4 BIENAIME JEAN JACQUES A - Award D 2,518
2025-06-10 INCY / Incyte Corporation 4 Clancy Paul J A - Award D 2,518
2025-06-10 INCY / Incyte Corporation 4 BAKER BROS. ADVISORS LP See Footnotes A - Award I 2,518
2025-06-10 INCY / Incyte Corporation 4 Schaffert Susanne A - Award D 2,518
2025-06-10 INCY / Incyte Corporation 4 BAKER BROS. ADVISORS LP See Footnotes A - Award I 2,518
2025-06-10 INCY / Incyte Corporation 4 BRAWLEY OTIS W A - Award D 2,518
2025-06-10 INCY / Incyte Corporation 4 FOUSE JACQUALYN A A - Award D 2,518
2025-06-10 INCY / Incyte Corporation 4 HARRIGAN EDMUND A - Award D 2,518
2025-06-10 INCY / Incyte Corporation 4 High Katherine A A - Award D 2,518
2025-06-05 CRL / Charles River Laboratories International, Inc. 4 LaPlume Joseph W G - Gift D -385
2025-06-03 INCY / Incyte Corporation 4 Denton Sheila A. S - Sale D 68 -1,795
2025-06-03 INCY / Incyte Corporation 4 Denton Sheila A. M - Exercise D 58.06 1,795
2025-06-02 NOTV / Inotiv, Inc. 4 Neff R Matthew S - Sale D 2.623 -2,000
2025-06-02 INCY / Incyte Corporation 4 Tray Thomas S - Sale D 64.88 -651
2025-06-02 CRL / Charles River Laboratories International, Inc. 4 Barg Steven A - Award D 135.04 946
2025-06-02 CRL / Charles River Laboratories International, Inc. 4 Barg Steven A - Award D 135.04 481
2025-06-02 CRL / Charles River Laboratories International, Inc. 4 Ceesay Abraham A - Award D 135.04 946
2025-06-02 CRL / Charles River Laboratories International, Inc. 4 Graves Paul W A - Award D 135.04 946
2025-06-02 CRL / Charles River Laboratories International, Inc. 4 Enyedy Mark J A - Award D 135.04 946
2025-06-01 NEO / NeoGenomics, Inc. 4/A HANNAH ALISON L. M - Exercise D 12,254
2025-06-01 NEO / NeoGenomics, Inc. 4 Floegel Elizabeth M - Exercise D 12,254
2025-06-01 NEO / NeoGenomics, Inc. 4 TETRAULT LYNN A. M - Exercise D 12,254
2025-06-01 NEO / NeoGenomics, Inc. 4 Williams Felicia M - Exercise D 7,160
2025-06-01 NEO / NeoGenomics, Inc. 4 Kelly Michael Aaron M - Exercise D 12,254
2025-06-01 NEO / NeoGenomics, Inc. 4 Gunn Neil M - Exercise D 12,254
2025-06-01 NEO / NeoGenomics, Inc. 4 Perez David Brian M - Exercise D 12,254
2025-06-01 NEO / NeoGenomics, Inc. 4 Zook Anthony P. M - Exercise D 12,254
P
Pembelian sekuritas non-derivatif atau derivatif di pasar terbuka atau secara pribadi.
S
Penjualan terbuka atau penjualan pribadi atas sekuritas non-derivatif atau derivatif.
A
Hibah, penghargaan, atau perolehan sekuritas lainnya dari perusahaan (seperti opsi)
C
Konversi turunan
D
Penjualan atau pengalihan sekuritas kembali ke perusahaan.
F
Pembayaran harga pelaksanaan atau kewajiban pajak menggunakan sebagian sekuritas yang diterima dari perusahaan.
G
Pemberian sekuritas oleh atau kepada orang dalam.
K
Swap ekuitas dan transaksi lindung nilai serupa
M
Pelaksanaan atau konversi sekuritas derivatif yang diterima dari perusahaan (seperti opsi)
V
Transaksi yang dilaporkan secara sukarela pada Formulir 4.
J
Lainnya (disertai dengan catatan kaki yang menjelaskan transaksi tersebut)